All In MedTech

Device Trial Radar · NCT05345444

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

May 26, 2022

Primary completion

Apr 24, 2026

Study completion Aug 2027

Sponsor

Lead sponsor
Weill Medical College of Cornell UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 25, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.

Conditions

  • Prostate Cancer

Interventions

  • IRE & MRgRTDevice

    Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility as measured by percentage of subjects assessed at 12 weeks post-IRETime frame: 12 weeks
  2. Feasibility as measured by percentage of subjects assessed at 6 weeks post-MRgRT within 1 yearTime frame: 6 weeks
  3. Proportion of patients who remain cancer-freeTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.